EAM Investors’s Kezar Life Sciences KZR Stock Holding History

EAM Investors’s Portfolio KZR Stock Details KZR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-29,356	Closed	-$4.88M	–	299
2022 Q1	$4.88M	Sell	29,356 -4,880	-14%	-$700K	0.91%	4
2021 Q4	$5.72M	Buy	+34,236	New	+$3.86M	0.94%	4

Other funds holding KZR

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

EAM Investors's KZR Position: Q2 2022 in Review

EAM Investors sold out of Kezar Life Sciences (KZR) in Q2 2022, closing a stake of 29,356 shares — an estimated $4.88M sold.

EAM Investors first reported a position in KZR in Q4 2021 and held it in 2 quarters. The position peaked at $5.72M in Q4 2021. 127 funds tracked by Wall St. Rank hold KZR as of Q2 2022.

EAM Investors reported no remaining Kezar Life Sciences position as of Q2 2022 after selling out during the quarter.
EAM Investors sold 29,356 Kezar Life Sciences shares in Q2 2022, an estimated $4.88M.
EAM Investors first reported a position in Kezar Life Sciences in Q4 2021 and held it in 2 quarters.
EAM Investors's Kezar Life Sciences position peaked at $5.72M in Q4 2021.
127 funds tracked by Wall St. Rank held Kezar Life Sciences as of Q2 2022.

Based on EAM Investors's 13F filing for Q2 2022, filed 12 Aug 2022.